Tim Robinson
@drtimrobinson.bsky.social
Consultant and senior lecturer in medical oncology, University of Bristol. Breast cancer, clinical trials and harm v benefit. Rides a bike sometimes
We have an open #PhD #studentship as part of our "Black Leaders in Cancer" programme at @crukconvergence.bsky.social & @icrlondon.bsky.social. About computational modelling of T-cell evolution in cancer. www.findaphd.com/phds/project... I'm looking forward to meeting prospective students #CRUKfunded
findaphd.com
The SONIA trial shows the utility of well-designed academic trials. But funding such studies is getting harder and harder. We need to work with industry to design smarter trials that don’t need further costly and lengthy trials to fill gaps www.nature.com/articles/d41... @oncoalert.bsky.social #bcsm
Toxicity and costs of cancer treatment reduced by deferring CDK4/6 inhibitor use
No difference in survival outcomes between use of CDK4/6 inhibitors as first- or second-line treatment in metastatic breast cancer.
nature.com
This is potentially very interesting data but follow up is short at this point and would want to see an EFS/OS outcome. Does provide early signal and could be useful for those where steroids are contraindicated or problematic
Elisa Agostinetto@elisaagostinetto.bsky.social · 2y agoOut in @TheLancetOncol De-escalated neoadjuvant CT with trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer PCR rate 66.3% vs. 57.6% in the nab-paclitaxel group vs. in the docetaxel + carbo group @oncoalert.bsky.social www.thelancet.com/journals/lan...
⏰ Final call! 🧑🔬 Last week to apply for this fantastic opportunity to work with the exceptional @giampazolias.bsky.social at @cruk-mi.bsky.social. #TeamManchester To apply (deadline 1 Dec 2024): www.cruk.manchester.ac.uk/recruitment/...
Index - CrukMi.RecruitmentHr.Ui
cruk.manchester.ac.uk
Jon Lim, FRCP PhD@drjonlim.bsky.social · 2y ago🧑🔬 Interested in #CancerImmunology? Looking for #postdoc position? Excellent opportunity to join us in Manchester to work with my close friend & collaborator @giampazolias.bsky.social - a superb scientist & group leader 💫! We have many things planned, including #TranslationalResearch. More info 👇
Nice review! I’m sure we will have combination strategies in the clinic on the next few years but must balance efficacy with cost/side effect profiles
Padmanee (Pam) Sharma, MD, PhD@pamsharmamdphd.bsky.social · 2y agowww.nature.com/articles/s41... Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Reassuring BUT short follow up at this time point
Daniel Stover, MD, FASCO@stoverlab.bsky.social · 2y agoStudy in #JAMAOnc from Scotland/Wales of nearly 50k #breastcancer patients suggests vaginal estrogen use *NOT* associated w increase risk of breast cancer-specific mortality. More reassuring data 👍 jamanetwork.com/journals/jam...
Interesting results, be nice to see these replicated in other eTNBC IO trials. Also to explore links with irAEs
Daniel Stover, MD, FASCO@stoverlab.bsky.social · 2y agoCorrelative analysis of GeparNuevo #TNBC neoadj clinical trial by Denkert et al: ➡️Expression analyses of tumor biopsies at 3 time points ➡️Confirm role of immune & prolif signatures ➡️Stromal signature assoc w immunotherapy resistance @oncoalert.bsky.social #BCSM www.cell.com/cell-reports...
Anecdotally, seeing an awful lot of younger patients with TNBC coming through MDT. Is anyone else seeing this?
I’m excited to see data at #SABCS but I’m also mindful that we are adding more and more to treatments and feel like we’re reaching the point that we need to start trying smarter patient selection to prevent harm @oncoalert.bsky.social #oncsky
We really need some better biomarkers for immunotherapy toxicity…. Im worried we’re storing up psome big issues down the line
Well this seems rather pleasant compared to… you know the other place